

ELECTRONICALLY FILED		
<b>DECLARATION OF JOFFRE B. BAKER UNDER 37 C.F.R. § 1.132</b>  Address to: Commissioner for Patents Alexandria, VA 22313-1450	Application No.	10/714,195
	Confirmation No.	5745
	First Named Inventor	Joffre B. Baker
	Atty Docket No.	GHDX-005
	Filing Date	November 14, 2003
	Group Art Unit	1634
	Examiner Name	A.M. Shaw
	Title	<i>Gene expression profiling of EGFR positive cancer</i>

Dear Sir:

1. I, Joffre B. Baker, declare and say I am a co-inventor of the claims of the above-identified patent application.

2. I have read the Office Action dated October 19, 2007 in this application and understand that the Examiner has rejected certain claims.

3. A Declaration under 37 C.F.R. §1.132 (the "December 21, 2006 Declaration") was submitted along with an amendment, filed on December 21, 2006 and responsive to the June 21, 2006 Office Action. The December 21, 2006 Declaration included two errors, as described below.

4. The December 21, 2006 Declaration stated, in paragraph 6, "After removal of the colon tumor tissue, the patients were treated with an EGFR inhibitor selected from erlotinib, gefitinib, cytoximab, EMB72000, AEE788..." This sentence should have read, "After removal of the colon tumor tissue, the patients were treated with an EGFR inhibitor selected from erlotinib, gefitinib, Cetuximab, EMD72000, AEE788..."

5. I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title XVIII of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

April 15, 2008  
Date

Joffre B. Baker  
Joffre B. Baker, Ph.D.